Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy

摘要: Objectives:  To evaluate the early quality of life outcomes in prostate cancer patients managed by high-dose-rate brachytherapy as monotherapy. Methods:  A total 51 with cT1c–T3aN0M0 treated between July 2007 and January 2010 were included this study. The average age was 69 years, initial serum prostate-specific antigen 10.98 ng/mL. 25, 18 eight considered to be low, intermediate high risk, respectively. All received one implant Ir-192 seven fractions 6.5 Gy within 3.5 days for a prescribed dose 45.5 Gy. For high-risk cancer, neoadjuvant androgen deprivation therapy carried out at least 6 months, continued after brachytherapy. Quality measured using International Prostate Symptom Score, Functional Assessment Cancer Therapy-Prostate Index Erectile Function Questionnaire. oncological outcome assessed diagnostic imaging. Adverse events also recorded. Results:  scores decreased few months brachytherapy, recovered pretreatment condition thereafter. Score significantly increased 2 weeks treatment each its items their sum, it returned baseline 12 weeks. Sexual function 2 4 weeks, Severe complications rare. Within median follow up 17.2 months, two showed recurrence. Conclusions:  High-dose-rate is feasible modality acceptable toxicity only limited impact on life.